Stock Alert for Radient Pharmaceuticals Corp. (RPC) " />

Stock Alert for Radient Pharmaceuticals Corp. (RPC)

Radient Pharmaceuticals Corp. (RPC) is a Tustin, Calif.-based company focused on the discovery, development and commercialization of diagnostic tests that help physicians answer clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. The Company offers its FDA-cleared In Vitro Diagnostic Onko-SureTest Kits for colon-rectal cancer recurrence monitoring.

RCP was incorporated in 1988.  It has two subsidiaries: AMDL Diagnostics Inc., which is also located in Tustin, California; and Jade Pharmaceuticals Inc., which is located in Shenzhen, China.

Share Statistics (22-Feb-11) FY












Symbol RPC Revenue, $Mn 23.77 8.63 -63.7% 2.71 0.03 -98.9%
Current price $0.73 Gross marg. 2.2% 37.9% 1622.7% 40.2%
52wk Range: $0.21-$2.59 Oper. margin -118.1% -9697.9%
Avg Vol (3m): 5,432,170 Net margin 5.0% -192.6% -3952.0% -189.3%
Market Cap. 26.83M
Shares Outstanding 36.76M EPS, $ -0.05 -0.67 1240..0% -0.24 -0.36 50.0%

Source:, SEC Filings.

Investment Highlights

Shares of RPC added $0.06, or 8.96%, to close at $0.73 Monday.  Approximately 11.08 million shares have traded hands Tuesday compared with the stock’s average daily volume of about 3.64 million shares. RPC has so far reached a 52-week high of $2.59, its 52-week low being $0.21.  It is currently trading below its 50-day moving average of $0.82 and above its 200-day moving average of $0.64. Market capitalization currently stands at $26.84 million and it has 36.76 million outstanding shares.

Late last month, RPC announced the signing of a definitive agreement for the private sale of Convertible Notes (Note) and Warrants (Warrant) in the original principal amount of $8.4 million and the right to purchase RPC common stock. The Company said it plans to use the net proceeds from the Note for general corporate purposes, including activities related to the long-term commercialization of its Onko-Sure in vitro diagnostic (IVD) cancer test. The $8.4 million of Note issued pursuant to this transaction has an 11-month term and will be initially convertible in whole or in part into shares of RPC common stock at the conversion price equal to $0.60 per share, subject to adjustment. Each buyer will pay $888.88 for each $1,000.00 of principal amount of Notes and related Warrants to be purchased at closing.

“This financing, when combined with the previously announced ongoing and anticipated debt conversions and exchanges, will put RPC in a dramatically improved financial position that allows for the rapid commercialization of our Onko-Sure® IVD cancer test,” said RPC chairman and CEO Douglas MacLellan.  “It also reflects the strong support from RPC investors that believe in the potential of our Onko-Sure IVD cancer test and have confidence in the Company’s management team and business strategy.

Two days later, RPC said it has completed the private sale of Convertible Notes (Note) and Warrants (Warrant) financing.  The Company has received approximately $7.5 million in gross proceeds pursuant to the sale of convertible notes pursuant to the securities purchase agreement with net proceeds from the financing of approximately $6.82 million.

Visit RPC at

Financial Summary

For the three-month period ending September 30, 2010, RPC reported revenues of approximately $34,446 compared with revenues of approximately $2.7 million in the third quarter of fiscal year 2009. RPC reported a comprehensive third-quarter loss of approximately $11.9 million ($0.39 per share) in the third quarter of fiscal year 2010, (of which approximately $11.5 million was due to interest expenses associated with the Company’s various debt financings), compared to approximately $5 million ($0.31 per share) for the same period in 2009.

Gross profits for the third quarter fiscal y ear 2010 decreased to approximately $27,749 compared to approximately $1.1 million for the same period in fiscal year 2009. Selling, general and administrative expenses were approximately $2.3 million for the third quarter of 2010 as compared to $3.3 million for the same period in fiscal year 2009, decreasing by approximately $1 million.


Financial Strength (22-Feb-2010) Company Industry Sector S&P 500
Quick Ratio (MRQ) 0.06 2.23 1.77 0.51
Current Ratio (MRQ) 0.06 2.92 2.20 0.82
LT Debt to Equity (MRQ) 16.88 15.83 107.37
Total Debt to Equity (MRQ) 26.71 20.65 151.63
Interest Coverage (TTM) -3.72 4.26 2.58 15.78

Source:, SEC Filings.

Analyst Consensus

No consensus analysis data available.


Technical Analysis


RPC is trading above its 20-day moving average. While this is normally considered to be a bullish sign, the moving average is downward sloping, which means that investors have been liquidating shares during this time period and tempers the bullishness of the signal.

RPC is trading near its upper Bollinger Band. This suggests that the stock price is high relative to its recent price action.

RPC’s MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below 0, which suggests that the underlying moving averages are bearish.

Comparative Analysis

Company Name Ticker Price per Mrkt. Cap. P/E P/S
Feb22-2011 symbol Share, $ $ Mn 2010 2011 2010 2011
Abbott Laboratories ABT 46.97 72.61B 10.23 9.53 1.91 1.84
Baxter International Inc. BAX 52.30 30.48B 12.45 11.34 2.27 2.16
Bio-Rad Laboratories Inc. BIO 110.36 3.07B 20.25 18.58 1.61 1.50
Beckman Coulter Inc. BEC 83.00 5.75B 21.17 20.44 1.57 1.51
Medical Instruments & Supplies Median 17.90 n/a 1.94 n/a
Radient Pharmaceuticals Corp. RPC 0.73 26.83M n/a n/a n/a n/a

Source: Thomson Financial

Source: Yahoo Finance

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

Leave a Reply

Your email address will not be published. Required fields are marked *